Protein Interaction and Cancer Lab (Acting Head). Our principal interest is cell surface proteins that promote tumour growth, in the context of the tumour microenvironment, and may be targeted by therapeutic antibodies. Our focus is on Eph receptor tyrosine kinases, due to their critical roles in tumour tissue patterning and stem cell maintenance, and on ADAM metalloproteases, which regulate signalling by diverse cell surface receptors including Ephs, erbBs and Notch. We employ various biochemical, structure/function and imaging techniques using tumour models in vitro and in vivo. Our antibodies against EphA3 and ADAM10 inhibit tumour growth in mice, and the EphA3 antibody is currently entering Phase II clinical trials.